Home » Stocks » PBYI

Puma Biotechnology Inc. (PBYI)

Stock Price: $10.97 USD -0.34 (-3.01%)
Updated Feb 25, 2021 2:05 PM EST - Market open
Market Cap 447.72M
Revenue (ttm) 235.48M
Net Income (ttm) -56.20M
Shares Out 39.70M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $10.97
Previous Close $11.31
Change ($) -0.34
Change (%) -3.01%
Day's Open 11.20
Day's Range 10.61 - 11.43
Day's Volume 189,549
52-Week Range 5.50 - 14.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 1 week ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PST on February 25 following release of its 4Q-2020 financial results.

Business Wire - 2 weeks ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards for the month of January 2021 as required by Nasdaq Listing Rule 5635(c)(4).

Business Wire - 3 weeks ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from the Phase II SUMMIT Trial of Neratinib for EGFR exon 18-mutated, metastatic NSCLC at WCLC 2020.

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present a company update at the B. Riley Oncology Investor Conference on Jan. 21.

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from its biliary tract cancers cohort of the Phase II SUMMIT “basket” trial at ASCO GI 2021,

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at the J.P. Morgan Healthcare Conference on Jan. 14 at 10:50 a.m. EST.

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present a Puma Biotechnology update at H.C. Wainwright's BioConnect VIRTUAL Conference beginning on Jan. 11, 2021 at 6:00 am EST.

Seeking Alpha - 1 month ago

Puma Biotechnology continues to report encouraging clinical data for its flagship product, NERLYNX. Unfortunately, the commercial numbers continue to remain in purgatory. I take a look at the ...

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards for November 2020 as required by Nasdaq Listing Rule 5635(c)(4) .

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented efficacy and safety outcomes from the Phase III NALA Trial in a Spotlight Poster at the 2020 Virtual SABCS.

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented final overall survival analysis from its Phase III ExteNET Trial at the 2020 San Antonio Breast Cancer Symposium.

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updated results from its Phase II SUMMIT trial in a Spotlight Poster at the 2020 San Antonio Breast Cancer Symposium.

Zacks Investment Research - 2 months ago

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present 10 posters at the 2020 Virtual San Antonio Breast Cancer Symposium, which will be held Dec. 8-11, 2020.

Zacks Investment Research - 3 months ago

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards for Oct. 2020 as required by Nasdaq Listing Rule 5635(c)(4).

Seeking Alpha - 3 months ago

Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Puma Biotech (PBYI) delivered earnings and revenue surprises of -139.39% and -4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology released interim results from its Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 mutated, metastatic NSCLC.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology reported its financial results for the third quarter and nine months ended Sept. 30, 2020.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will provide a corporate update at the Credit Suisse Virtual Healthcare Conference on Nov. 10

Zacks Investment Research - 3 months ago

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)--On November 5, 2020, Puma Biotechnology will issue its 3Q-2020 financial results after market close and host a conference call at 1:30 p.m. PST.

PRNewsWire - 4 months ago

PLYMOUTH MEETING, Pa., Oct. 15, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of t...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)--Overall survival results from Puma Biotechnology's Phase III ExteNET trial were published online in Clinical Breast Cancer.

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--On September 8, 2020, a Court-appointed administrator confirmed the claims of more than 4,600 individual and institutional investors defrauded by Puma Biotechnology...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO Alan Auerbach will provide a company overview at the virtual H.C. Wainwright Global Conference on September 15, 2020.

Zacks Investment Research - 5 months ago

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)--A manuscript including results from Puma Biotechnology's CONTROL trial was published in the September 2020 issue of Annals of Oncology.

Seeking Alpha - 6 months ago

Puma Bio: A Contrarian Investment That Requires Patience

Zacks Investment Research - 6 months ago

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

Seeking Alpha - 6 months ago

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Puma Biotech (PBYI) delivered earnings and revenue surprises of 130.77% and 26.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of Puma Biotechnology (NASDAQ:PBYI) rose 0.32 in after-market trading after the company reported Q2 results.

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)--On Aug. 6, 2020, Puma Biotechnology released its financial results for the third quarter and six months ended June 30, 2020.

Business Wire - 6 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's P 2 SUMMIT trial results of neratinib in HER2-Mutant, metastatic cervical cancers were published online in Gynecologic Oncology.

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will release its financial results and host a conference call after the close of U.S. markets on August 6, 2020.

Business Wire - 7 months ago

IRVING, Texas--(BUSINESS WIRE)--Acentrus Specialty finalizes an agreement with Puma Biotechnology, Inc. to provide qualified Acentrus clients access to NERLYNX® (neratinib).

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's licensing partner Specialised Therapeutics Asia received authorization to market NERLYNX in Malaysia.

Investors Business Daily - 7 months ago

Puma Biotechnology shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 86. The post Puma Biotechnology Clears Technical Benchmark, Hitting 80-P...

Zacks Investment Research - 8 months ago

We have zeroed in on five stocks that have witnessed a slump this past week but have a favorable Zacks Rank #1 (Strong Buy) or 2 (Buy).

Other stocks mentioned: ADNT, PRDO, STNG, UNFI
Zacks Investment Research - 8 months ago

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 8 months ago

Puma Biotechnology, Inc. (PBYI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 9 months ago

Puma Biotechnology: Still Bullish At These Prices

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Puma Biotechnology, Inc. (PBYI).

Zacks Investment Research - 9 months ago

Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.

Seeking Alpha - 9 months ago

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Puma Biotech (PBYI) delivered earnings and revenue surprises of 45.57% and 16.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

About PBYI

Puma Biotechnology, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction t... [Read more...]

Industry
Biotechnology
Founded
2010
CEO
Alan H. Auerbach
Employees
269
Stock Exchange
NASDAQ
Ticker Symbol
PBYI
Full Company Profile

Financial Performance

In 2019, PBYI's revenue was $272.26 million, an increase of 8.47% compared to the previous year's $250.99 million. Losses were -$75.60 million, -33.44% less than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for PBYI stock is "Hold." The 12-month stock price forecast is 10.33, which is a decrease of -5.83% from the latest price.

Price Target
$10.33
(-5.83% downside)
Analyst Consensus: Hold